The MoCA
Well-suited screen for cognitive impairment in Parkinson disease
Citation Manager Formats
Make Comment
See Comments
![Loading Loading](https://n.neurology.org/sites/all/modules/contrib/panels_ajax_tab/images/loading.gif)
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Abstract
Objective: To establish the diagnostic accuracy of the Montreal Cognitive Assessment (MoCA) when screening externally validated cognition in Parkinson disease (PD), by comparison with a PD-focused test (Scales for Outcomes in Parkinson disease–Cognition [SCOPA-COG]) and the standardized Mini-Mental State Examination (S-MMSE) as benchmarks.
Methods: A convenience sample of 114 patients with idiopathic PD and 47 healthy controls was examined in a movement disorders center. The 21 patients with dementia (PD-D) were diagnosed using Movement Disorders Society criteria, externally validated by detailed independent functional and neuropsychological tests. The 21 patients with mild cognitive impairment (PD-MCI) scored 1.5 SD or more below normative data in at least 2 measures in 1 of 4 cognitive domains. Other patients had normal cognition (PD-N).
Results: Primary outcomes using receiver operating characteristic (ROC) curve analyses showed that all 3 mental status tests produced excellent discrimination of PD-D from patients without dementia (area under the curve [AUC], 87%–91%) and PD-MCI from PD-N patients (AUC, 78%–90%), but the MoCA was generally better suited across both assessments. The optimal MoCA screening cutoffs were <21/30 for PD-D (sensitivity 81%; specificity 95%; negative predictive value [NPV] 92%) and <26/30 for PD-MCI (sensitivity 90%; specificity 75%; NPV 95%). Further support that the MoCA is at least equivalent to the SCOPA-COG, and superior to the S-MMSE, came from the simultaneous classification of the 3 PD patient groups (volumes under a 3-dimensional ROC surface, chance = 17%: MoCA 79%, confidence interval [CI] 70%–89%; SCOPA-COG 74%, CI 62%–86%; MMSE-Sevens item 56%, CI 44%–68%; MMSE-World item 62%, CI 50%–73%).
Conclusions: The MoCA is a suitably accurate, brief test when screening all levels of cognition in PD.
Footnotes
-
Study funding: Supported by the Neurological Foundation of New Zealand (T.J.A., J.C.D.-A., R.W., R.P., M.R.M., J.K., S.W.), the Canterbury Medical Research Foundation (T.J.A., J.C.D.-A., M.R.M., R.W., R.K.), and the Neurology Trust (T.J.A., L.L.).
-
- ADAS-Cog
- Alzheimer's Disease Assessment Scale–Cognition
- AUC
- area under the curve
- CDR
- Clinical Dementia Rating
- CI
- confidence interval
- DRS-2
- Dementia Rating Scale–2
- MDS
- Movement Disorders Society
- MMSE
- Mini-Mental State Examination
- MoCA
- Montreal Cognitive Assessment
- NPV
- negative predictive value
- PD
- Parkinson disease
- PD-D
- Parkinson disease with dementia
- PD-MCI
- Parkinson disease with mild cognitive impairment
- PD-N
- Parkinson disease with normal cognition
- R-IADL
- Reisberg instrumental activities of daily living
- ROC
- receiver operating characteristic
- S-MMSE
- standardized Mini-Mental State Examination
- SCOPA-COG
- Scales for Outcomes in Parkinson disease–Cognition
- VUS
- volume under a surface
- Received April 12, 2010.
- Accepted July 20, 2010.
- Copyright © 2010 by AAN Enterprises, Inc.
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)
Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here
Purchase
Individual access to articles is available through the Add to Cart option on the article page. Access for 1 day (from the computer you are currently using) is US$ 39.00. Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means. The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use. Distributing copies (electronic or otherwise) of the article is not allowed.
Letters: Rapid online correspondence
- The MoCA: Well-suited screen for cognitive impairment in Parkinson disease
- Johan Marinus, Senior Researcher, Leiden University Medical Centerj.marinus@lumc.nl
- Dagmar Verbaan, Jacobus J. van Hilten
Submitted February 02, 2011 - Reply from the authors
- John C. Dalrymple-Alford, Associate Professor, Van der Veer Institute for Parkinson's and Brain Researchjohn.dalrymple-alford@canterbury.ac.nz
- C.T. Nakas, PhD, M.R. MacAskill, PhD, L. Livingston, BA, and T.J. Anderson, MD
Submitted February 02, 2011
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Long-term Safety and Efficacy of Avalglucosidase Alfa in Patients With Late-Onset Pompe Disease
Dr. Marianne de Visser and Dr. Maudy Theunissen
► Watch
Related Articles
- No related articles found.
Topics Discussed
Alert Me
Recommended articles
-
Articles
Validity of the MoCA and MMSE in the detection of MCI and dementia in Parkinson diseaseS. Hoops, S. Nazem, A. D. Siderowf et al.Neurology, November 23, 2009 -
Article
Cognitive impairment and PD patients' capacity to consent to researchJason Karlawish, Mark Cary, Stephen T. Moelter et al.Neurology, July 26, 2013 -
Article
Potential sex differences in nonmotor symptoms in early drug-naive Parkinson diseaseRui Liu, David M. Umbach, Shyamal D. Peddada et al.Neurology, April 29, 2015 -
Article
CSF Aβ42 predicts early-onset dementia in Parkinson diseaseGuido Alves, Johannes Lange, Kaj Blennow et al.Neurology, April 18, 2014